Your browser is no longer supported. Please, upgrade your browser.
Clene Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own11.10% Shs Outstand59.53M Perf Week-5.66%
Market Cap775.54M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float38.76M Perf Month96.03%
Income-0.90M PEG- EPS next Q- Inst Own1.00% Short Float0.29% Perf Quarter18.34%
Sales0.18M P/S4381.56 EPS this Y-4.60% Inst Trans-72.20% Short Ratio0.49 Perf Half Y17.05%
Book/sh9.92 P/B1.29 EPS next Y- ROA-2.30% Target Price- Perf Year27.76%
Cash/sh0.01 P/C1938.84 EPS next 5Y- ROE-2.50% 52W Range6.23 - 17.50 Perf YTD42.51%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-26.63% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low106.10% ATR1.35
Employees62 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)55.67 Volatility10.04% 14.19%
OptionableNo Debt/Eq0.09 EPS Q/Q-321.00% Profit Margin- Rel Volume0.26 Prev Close13.03
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume229.66K Price12.84
Recom- SMA2011.69% SMA5030.02% SMA20022.13% Volume59,676 Change-1.46%
Mar-01-21 07:00AM  
Feb-25-21 07:31AM  
Feb-19-21 07:00AM  
Feb-16-21 07:00AM  
Jan-19-21 07:00AM  
Dec-30-20 05:38PM  
Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.